Axsome Therapeutics announced that the company’s AXS-05 met the primary endpoint in the ADVANCE-1 Phase II/III clinical trial for agitation in patients with Alzheimer’s disease.
When major depressive disorder does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it’s reclassified as treatment-resistant depression (TRD). South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet the primary efficacy endpoints for TRD in a Phase II clinical trial.
Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.
One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced that the company was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million.
EVANSTON, Ill., Sept. 16, 2015 /PRNewswire/ — Aptinyx Inc., a biopharmaceutical company advancing modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging disorders of the brain and nervous system, has launched with the discovery platform and preclinical pipeline spun out of Naurex upon the close of its acquisition by Allergan in August 2015. “As […]